All In Biotech

Drug Trial Radar · NCT01374490

Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea

A Phase 3, Multicenter, Open-Label Evaluation of the Safety and Tolerability of Crofelemer in HIV-Positive Subjects With Diarrhea

Last checked: Nov 19, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Jun 7, 2011

Primary completion

Oct 31, 2012

Study completion Oct 31, 2012

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jun 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.

Conditions

  • HIV Enteropathy
  • Diarrhea With HIV

Interventions

  • CrofelemerDrug

    Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).Time frame: 48 weeks

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Bakersfield, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Wilton Manors, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Detroit, Michigan

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.